文献速递银屑病与炎症性皮肤病

银屑病生物制剂药物存活率与药物可及性相关

Drug survival in patients with psoriasis is associated with the availability of biologic medications.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2020-02-19

本研究基于Clalit健康服务数据库,对2002-2018年间接受阿达木单抗、英夫利西单抗、依那西普、乌司奴单抗和司库奇尤单抗治疗的中重度银屑病患者进行生存分析。共纳入1459例患者的3070个生物制剂治疗疗程,乌司奴单抗的粗存活率显著高于TNF-α抑制剂和司库奇尤单抗。校正治疗线数等因素后,乌司奴单抗与司库奇尤单抗的差异不再显著,提示药物存活率差异受治疗线和日历年(反映生物制剂可及性)影响,而非仅由药物本身特性决定。

要点

  • 乌司奴单抗平均药物存活43.5个月,司库奇尤单抗17.1个月,粗存活率差异显著。
  • 生物制剂药物存活率差异受治疗线和日历年(反映药物可及性)影响,非仅药物特性。

核心结论

  • 乌司奴单抗与司库奇尤单抗之间的药物存活率差异由治疗线和日历年决定,反映生物制剂的可及性,而不仅仅是每种药物的生物学特性。

研究设计与样本

  • 基于Clalit健康服务数据库的生存分析,纳入2002-2018年接受阿达木单抗、英夫利西单抗、依那西普、乌司奴单抗和司库奇尤单抗治疗的中重度银屑病患者1459例,共3070个生物制剂治疗疗程。
  • 按生物制剂治疗线数进行分层分析,多因素分析校正人口学变量、日历年、代谢综合征、银屑病关节炎、生物制剂治疗线数、生物制剂初治状态、口服治疗联用及既往口服系统治疗暴露。

主要发现

  • 乌司奴单抗的粗存活率显著高于TNF-α抑制剂和司库奇尤单抗。

临床怎么用

  • 解读生物制剂药物存活率数据时需考虑治疗线和药物可及性等混杂因素,避免仅归因于药物本身特性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Drug survival rates in patients with psoriasis had been described extensively. Different survival rates of TNF-α inhibitors (TNFIs), ustekinumab and secukinumab were reported. OBJECTIVES: To investigate drug survival rates of TNFIs, ustekinumab and secukinumab, with particular emphasis on the difference between ustekinumab and secukinumab. METHODS: Survival analysis was performed in patients with moderate-to-severe psoriasis who received adalimumab, infliximab, etanercept, ustekinumab and secukinumab treatment in 2002-2018, using the Clalit Health Services database. Stratified analysis was performed according to biologic treatment lines. Multivariate analysis was performed adjusting for demographic variables, calendar year, metabolic syndrome, psoriatic arthritis, biologic treatment line, biologic naivety, co-administration of oral treatments and previous oral systemic treatment exposure. RESULTS: Among 1459 patients treated with 3070 biologic medication courses, ustekinumab had a significantly higher crude survival as compared with TNFIs and secukinumab. The mean drug survival of ustekinumab, adalimumab, etanercept, infliximab and secukinumab was 43.5 (CI: 39.7-47.2), 38.2 (CI: 34.8-41), 33.9 (CI: 30.8-37.1), 28.2 (CI: 22.5-33.8) and 17.1 (CI: 15.6-18.6) months, respectively, with significant statistical differences for all comparisons (P < 0.001). The differences between ustekinumab and secukinumab were not significant following adjustment to factors that included treatment line (hazard rate 1.16, CI: 0.93-1.43). CONCLUSION: Different drug survival rates between ustekinumab and secukinumab are determined by the treatment line and calendar year, reflecting the availability of biologic medications, and not only by the biologic attributes of each medication.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Shalom G, Cohen AD, Feldhamer I, et al. Drug survival in patients with psoriasis is associated with the availability of biologic medications. J Eur Acad Dermatol Venereol. 2020. PMID: 31953883. doi:10.1111/jdv.16205

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。